InflaRx’s (IFRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

InflaRx Price Performance

InflaRx stock opened at $1.57 on Wednesday. The stock’s 50-day moving average is $1.49 and its 200-day moving average is $1.50. The company has a market cap of $92.45 million, a price-to-earnings ratio of -2.01 and a beta of 1.57. InflaRx has a 12 month low of $1.14 and a 12 month high of $3.08.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.04 million. InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. Research analysts anticipate that InflaRx will post -0.98 EPS for the current year.

Institutional Investors Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC lifted its stake in shares of InflaRx (NASDAQ:IFRX) by 2.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the quarter. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.